Open AccessMotion Sickness Treatment Analysis with OVAR
Author(s) -
Knox Glenn W.
Publication year - 2012
Publication title -
otolaryngology–head and neck surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.232
H-Index - 121
eISSN - 1097-6817
pISSN - 0194-5998
DOI - 10.1177/0194599812451438a168
Subject(s) - motion sickness , placebo , scopolamine , medicine , transdermal , anesthesia , visual analogue scale , pharmacology , psychiatry , alternative medicine , pathology
Objective Evaluation of transdermal scopolamine for motion sickness prophylaxis. Method Randomized, prospective double blind. 2010‐11. Twelve patients, 7 male, 5 female, ages 21 to 57. Intervention(s): Off‐vertical axis rotation 20° in the dark after administration of transdermal scopolamine or placebo. Outcome measures: Duration of tolerated off‐vertical rotation; subjective symptom reporting at 1‐minute intervals on a 0 to 4 scale. Results Patients treated with transdermal scopolamine had statistically significant improved tolerance time to off‐vertical axis rotation. Reported symptomatology on the 0‐3 subjective symptom scale was significantly improved as compared to placebo and was dose‐dependent. These results were significant to the. 05 confidence level. Conclusion Off‐vertical axis rotation is a useful modality for the evaluation of motion sickness medications. Transdermal scopolamine showed statistically significant dose‐dependent effects in mitigating OVAR‐induced motion sickness symptomatology and was well tolerated.